Retatrutide tracker: what to log while the drug is still in trials
Retatrutide is not on the market. It is an investigational triple agonist, still in clinical trials as of August 2026, with no FDA label and no approved dose. That does not make a tracker pointless, it makes it early. The habits you build around a weekly shot carry into whatever you end up taking.
Setva is on its way to the App Store. The curve calculator on this site is free today.
Retatrutide is an investigational weekly injection, not FDA approved as of August 2026, so there is no approved dose and no label half-life to track against. A phase 1b trial reported a half-life of about 6 days. If it reaches the market, a retatrutide tracker would need the dose, the injection site, side effects by day of the cycle, and weight.
Where retatrutide actually stands
Retatrutide is not approved by the FDA. As of August 2026 it is investigational: no label, no dose list, no pharmacy that can fill it. Everything below is in the conditional on purpose.
It is studied as a weekly injection acting on three receptors instead of one. Phase 2 results have been published in the New England Journal of Medicine.
- Status: investigational, not FDA approved as of August 2026
- Class: triple GIP, GLP-1 and glucagon receptor agonist
- Studied route: weekly injection
- Approved doses: none, which is why Setva publishes no dose list
- Half-life: about 6 days from a phase 1b trial, not from a label
The half-life figure is a sketch, not a label value
The number you will see quoted is about 6 days. It comes from a phase 1b multiple ascending dose trial, in a small group, at doses never meant to be final.
That is a different grade of evidence from an approved label, where semaglutide sits at about 7 days and tirzepatide at about 5. Those went through a label review. Retatrutide has not.
That is why Setva draws no retatrutide curve. The calculator on this site only covers medications with a half-life from an approved label. Any curve you see elsewhere is a sketch, not a measurement of your blood.
Why day 2 and day 6 are not the same week
A weekly drug with a half-life near 6 days does not sit at one level. It rises after the shot, holds near a peak, then drifts down until the next one lands. Week after week the low point stops falling all the way back, because the last dose has not cleared.
That gap between day 2 and day 6 is the whole reason a log is worth keeping. Most trackers record that a dose happened. They do not record which day of the cycle you were on when you felt it.
Side effects belong to a day, not to a month
Nausea, fatigue, reflux, constipation, headache. Those are the chips a tracker in this class carries, and side effect logging is where it earns its keep.
One tap per symptom with an intensity takes seconds. Two months later it is a pattern: the same chip landing on the same day of the dose cycle, until the sentence writes itself. It hits you on day 2. That is your own record telling you what next Tuesday looks like.
Forgetting the shot is the real failure mode
A weekly medication has one specific weakness. No daily rhythm holds it up. You take it, nothing happens for six days, the week gets busy, and later you are reconstructing whether that was this Thursday or the last.
What helps is small. One notification on dose day, marked time sensitive so it comes through a focus mode. One more nudge later if nothing has been logged. Then quiet. No third alarm, no streak to break.
Health data that never leaves your iPhone
What you take, how much, where you injected it, what it did to your stomach, what you weigh. That is a medical record in everything but name.
Setva has no accounts, no login and no server of ours. Your entries live on your iPhone and in your private iCloud, and we never see them.
How Setva tracks retatrutide
Setva is an iPhone app for people on GLP-1 treatment, built around the week between doses rather than around your weight.
Setva is not on the App Store yet. Be first when it launches by joining the waitlist. The price will be 79.99 USD a year or 12.99 USD a week, with no trial.
The curve calculator on this site is free today, needs no signup and runs in your browser. It covers the medications with a label half-life, not retatrutide: https://setva.app/glp-1-calculator
- Log a weekly injection or a daily tablet in two taps, with the site tracked on a body map.
- See the estimated curve for medications with a label half-life, always marked as an educational estimate.
- Tap symptom chips with an intensity and watch the pattern by day of the cycle build itself.
- Weight with a 7 day moving average, HealthKit, widgets, a Live Activity and an Apple Watch app.
- One reminder on dose day, one nudge if you have not logged it, then nothing.
Setva is coming to the App Store. Join the waitlist and you will hear from us once, the day it goes live.
Questions people ask
Is retatrutide FDA approved?
No. As of August 2026 it is investigational, with no FDA approval, no label and no approved dose.
Can I get retatrutide right now?
Not through a pharmacy. There is no FDA approved supply, so outside a clinical trial there is nothing a prescriber can fill. Anything sold elsewhere has not been through FDA review.
What is the half-life of retatrutide?
About 6 days in a phase 1b trial, not from an FDA label, so treat it as preliminary. For comparison, semaglutide is about 7 days and tirzepatide about 5.
How is retatrutide different from Mounjaro or Zepbound?
Tirzepatide, sold as Mounjaro and Zepbound, acts on GIP and GLP-1. Retatrutide adds the glucagon receptor. The larger difference is that tirzepatide is approved and retatrutide is not.
Can I use Setva to track retatrutide?
Yes, if you are in a trial and your trial team is comfortable with you keeping your own log. Setva records the dose, the date, the site, symptoms and weight, and draws no curve for retatrutide.
Does Setva tell me what dose to take?
No. Setva never suggests a dose, a change, a skip or a split. It records what you took. Dose decisions belong to you and your prescriber.
Is the curve a blood test?
No. It is a one compartment model built from published half-life data and the doses you enter, never a measurement of your blood. Setva draws none for retatrutide, whose half-life figure is not from a label.
Is Setva available yet, and what does it cost?
Not yet. It is on its way to the App Store, iPhone only, at 79.99 USD a year or 12.99 USD a week.
This is an educational estimate based on published half-life data, not a measurement of your blood. Never change your dose without your prescriber.